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Abstract Cardiac hypertrophy is an adaptive enlarge-
ment of the myocardium in response to altered stress or
injury. The cellular responses of cardiomyocytes and non-
cardiomyocytes to various signaling pathways should be
tightly and delicately regulated to maintain cardiac
homeostasis and prevent pathological cardiac hypertrophy.
MicroRNAs (miRNAs) are endogenous, single-stranded,
short non-coding RNAs that act as regulators of gene
expression by promoting the degradation or inhibiting the
translation of target mRNAs. Recent studies have revealed
expression signatures of miRNAs associated with patho-
logical cardiac hypertrophy and heart failure in humans and
mouse models of heart diseases. Increasing evidence
indicates that dysregulation of specific miRNAs could alter
the cellular responses of cardiomyocytes and non-cardio-
myocytes to specific signaling upon the pathological
hemodynamic overload, leading to cardiac hypertrophy and
heart failure. This review summarizes the cell-autonomous
functions of cardiomyocyte miRNAs regulated by different
pathways and the roles of non-cardiomyocyte miRNAs in
cardiac hypertrophy. The therapeutic effects of a number of
miRNAs in heart diseases are also discussed.
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Introduction
The heart is the first organ to form, and becomes functional
during vertebrate embryonic development. Embryonic
myocardial precursor cells from different origins give rise
to different cell types, including cardiac and smooth mus-
cle cells, valvular pacemaker, and endothelial cells, which
coordinately build a functional heart [1]. Once developed,
the homeostasis of adult heart is maintained by dynamic
remodeling in response to altered stress or injury. Upon
various mechanical, hemodynamic, hormonal, and patho-
logic stimuli, the cardiomyocytes initiate a hypertrophic
response triggered by a complex cascade of signaling
pathways to adapt to stress and improve the function of
heart [2]. Compared to the physiologic hypertrophy, which
involves proportional increases in the length and width of
cardiac myocytes, prolonged concentric or eccentric
hypertrophy is usually associated with enhanced synthesis
of proteins, assembly of sarcomeres, and both perivascular
and interstitial fibrosis, increased expression of embryonic
genes including natriuretic peptide and fetal contractile
protein genes, and eventually leads to heart failure [3].
Thus, a better understanding of the molecular mechanisms
underlying pathological hypertrophy will greatly benefit
rational drug development for heart failure treatment.
Recently, increasing evidence has revealed that micro-
RNAs (miRNAs) play important regulatory roles in cardiac
development and disease [4, 5]. MiRNAs are endogenous
small non-coding RNAs of 18–25 nt in length. They exert
biological functions by post-transcriptional regulation of
gene expression in a sequence-specific manner. MiRNAs
are transcribed mainly by RNA polymerase II as pri-
miRNAs that are usually several thousand bases in
length. The pri-miRNAs are subsequently processed in the
nucleus into a 70–100 nt hairpin RNAs (pre-miRNAs) by
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the RNase III-type enzyme Drosha, and cleaved by Dicer
in the cytoplasm, to form the mature double-stranded
miRNAs [6]. One strand of the mature miRNA is incorporated
into the miRNA-induced silencing complex (miRISC) to
bind target mRNA through its seed sequence. Binding of
mature miRNAs to mRNAs usually results in the repres-
sion of target gene expression by either degrading the
target mRNA or inhibiting the translation [6]. Each miRNA
could repress up to hundreds of transcripts, and it is thus
hypothesized that miRNAs form large-scale regulatory
networks across the transcriptome through miRNA response
elements (MREs) [7].
MiRNAs are differentially and temporally regulated
during cardiac hypertrophy and heart failure. In vivo gain-
and loss-of-function miRNA studies in mouse have dem-
onstrated physiological and pathogenic roles of miRNAs in
cardiac hypertrophy. Most importantly, in vivo manipula-
tion of miRNAs by a specific antagomir or mimic provides
new opportunities for therapeutic treatment for cardiac
hypertrophy and heart failure. This review describes the
biological functions and mechanisms of miRNAs in car-
diac hypertrophy, and highlights the possibility for
miRNAs as therapeutic targets for cardiac hypertrophy.
Dysregulation of miRNAs in cardiac hypertrophy
The dysregulation of miRNAs has been demonstrated in
cardiac hypertrophy by a series of high-throughput miRNA
microarray analyses [8–11]. The earliest array study was
performed based on two mouse models of pathological
hypertrophy: the transverse aortic constriction (TAC) mouse
model, an in vivo model of hypertrophy induced by left
ventricular pressure-overload, and the calcineurin transgenic
mouse model, a calcium-dependent model of maladaptive
response. The results showed that a specific group of
miRNAs were similarly dysregulated in both models. The
altered pattern of miRNA expression in the hypertrophic
mouse heart largely mimics that of the idiopathic end-stage
failing human heart, indicating that specific miRNAs repre-
sent a molecular signature of cardiac hypertrophy and might
have critical roles during the pathological process [8]. Further
miRNA profiling studies revealed that the expression of the
dysregulated miRNAs progressively changes during devel-
opment of pressure-overload cardiac hypertrophy [9].
MiRNA array analyses also demonstrate that the alter-
ations of a set of fetal miRNAs substantially contribute to
reactivation of fetal gene programs in the failing human
heart [10]. The altered expression of miRNAs in failing
hearts closely resembles the miRNA expression signature
observed in fetal cardiac tissue. A significant inverse cor-
relation exists between miRNAs and their regulated mRNA
expression in heart failures. Overexpression of specific
fetal miRNAs in cultured cardiomyocytes triggers fetal
gene expression and induces cellular hypertrophy, sug-
gesting that altered miRNAs might have important roles in
initiating cardiac hypertrophy.
MiRNA expression profiling studies have revealed novel
miRNA-based pathways underlying the cardiac diseases.
One piece of evidence from bioinformatics shows that the
eight dysregulated miRNAs in human heart failure might
affect 1,716 predicted targets, which associate with diverse
signaling networks [11]. The results suggest that cardiac
miRNAs are integrated into complex regulatory networks,
and dysregulation of miRNAs can affect multiple cellular
processes in ways that are conducive to the establishment
of cardiac diseases.
Cell-autonomous function of miRNAs in cardiac
hypertrophy
Various injuries and stresses stimulate a pathological gene
response and hypertrophic growth in adult cardiomyocytes,
often leading to heart failure and sudden death. Altered
cellular responses of cardiomyocytes to specific signaling
pathways might eventually hamper the cardiac perfor-
mance in the failing heart. The molecular mechanisms
underlying cardiac hypertrophy and heart failure have been
extensively studied, and many pathways involved in these
processes have been uncovered, such as thyroid hormone,
IGF1/Akt, calcineurin/NFAT and TGF-b/Smad-signaling
pathways. Recent studies have shown that miRNAs regu-
lated by these signaling pathways are involved in the
process of cardiac hypertrophy (Fig. 1).
MiRNAs regulated by thyroid hormone
Thyroid hormones have complex and important effects on
the cardiovascular system [12]. Increased thyroid hormones
can induce physiological hypertrophy characterized by
increased gene encoding of the calcium pump of the sarco-
plasmic reticulum (SERCa2), increased myosin heavy chain
a (a-MHC, a fast myosin) levels, and decreased b-MHC
levels, while a downregulation of the thyroid hormone sig-
naling system is associated with concentric cardiac
hypertrophy and heart failure [13]. Recently, a family of
miRNAs (miR-208a, miR-208b, and miR-499) encoded by
MHC genes, has been shown to form an intricate regulatory
circuit together with their host genes to regulate cardiac
hypertrophy. These miRNAs are co-expressed and are reg-
ulated together with their host MHC genes by the same
transcriptional events and signaling pathways. Treatment of
thyroid hormones significantly upregulates a-MHC/miR-
208a expression and reduces b-MHC/miR-208b expression
[14]. miR-208a is a cardiac-specific miRNA encoded by
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intron 27 of the a-MHC gene and regulates two slow myosins
and their intronic miRNAs, b-MHC/miR-208b and Myh7b/
miR-499. miR-208b is encoded within intron 31 of b-MHC
gene, while miR-499 is encoded by intron 19 of the mouse
Myh7b gene, which shares high homology with the b-MHC
gene [15]. miR-208b and miR-499 play redundant roles in
the specification of muscle fiber identity by activating slow
myofiber and repressing fast myofiber gene programs. Tar-
geted disruption of miR-208a in mice diminishes the re-
expression of the fetal b-MHC gene in response to stress and
hypothyroidism, and protects the heart from pathological
hypertrophy [16]. Consistently, transgenic overexpression
of miR-208a in the heart induces hypertrophic growth in
mice by suppressing thyroid hormone-associated protein 1
and myostatin, which are negative regulators of muscle
growth and hypertrophy [14]. Elevated levels of miR-499 in
the heart alter the cardiac response to stress in part by
modulating the immediate early response genes, and lead to
cardiomyocyte hypertrophy and cardiomyopathy in a dose-
dependent manner, especially in the setting of pressure
overload [17]. These studies have demonstrated that specific
miRNA upregulation can lead to cardiac hypertrophy caused
by dysregulation of thyroid hormone signaling.
MiRNAs regulated by IGF-1 signaling
The IGF-1/phosphoinositide 3-kinase (PI3K)-Akt signaling
plays an important function during physiological cardiac
remodeling [18]. To initiate the intracellular response to
IGF-1 signaling, activated intrinsic receptor tyrosine
kinases phosphorylate a number of intracellular substrates
such as the insulin receptor substrate-1 and Shc, which
recruit and activate downstream signaling pathways
including PI3K/Akt cascades. Dysregulation of IGF-1
signaling has also been involved in pathological hypertro-
phy [19]. Recent studies have revealed that miRNAs play
critical roles in mediating the effects of the IGF-1 pathway
in physiological and pathological conditions of heart. MiR-1
and miR-133 have been shown to be down-regulated in
exercised trained rats and cardiac-specific Akt transgenic
mice, which are models of physiological cardiac hyper-
trophy [20, 21]. The miR-1 has been further demonstrated
to be down-regulated by IGF-1 stimulation depending on
the Foxo3 transcription factor. Reciprocally, miR-1 con-
trols the expression of IGF-1 and IGF-1 receptor protein
levels by translation. Importantly, miR-1 expression cor-
relates inversely with overproduced growth hormone and
IGF-1, as well as dramatically increased cardiac myocyte
size in cardiac biopsies of patients with acromegaly,
demonstrating the clinical relevance of a feedback loop
between miR-1 expression and the IGF-1 signal transduction
pathway in human cardiac hypertrophy [22]. Consistently,
liver-specific IGF-1-deficient mice resist abdominal aortic
constriction (AAC)-induced cardiac hypertrophic and con-
tractile changes via alleviating down-regulation of miR-1 and
miR-133a [23].
Fig. 1 Cell-autonomous function of cardiomyocyte miRNAs in
cardiac hypertrophy. Multiple signaling pathways, including the
thyroid hormone, IGF-1, TGF-b, and calcineurin cascades control the
hypertrophic response of cardiomyocytes in the heart in response to
various stresses. The miRNAs regulated by these signaling pathways
are depicted
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MiRNAs regulated by TGF-b signaling
The transforming growth factor-b (TGF-b) superfamily
contains more than 40 ligands, which signal through
receptor serine/threonine kinases and intracellular Smad
proteins. The role of TGF-b signaling in cardiac hyper-
trophy has been extremely contradictory due to the
complexity of TGF-b activation as well as its diverse
effects on different type of cells. Although TGF-b1 has
been considered as detrimental, inducing cardiac hyper-
trophy and failure in the adult heart [24, 25], increasing
evidence shows that endogenous TGF-b/Smad signaling
protect cardiomyocyte from hypertrophic growth [26–29].
We have previously shown that targeted deletion of Smad4,
the central intracellular mediator of TGF-b superfamily
signaling, in cardiomyocyte, unexpectedly leads to cardiac
hypertrophy [26]. For the first time, the result provides in
vivo genetic evidence demonstrating that the endogenous
cardiomyocyte Smad4-dependent TGF-b pathway protects
heart from cardiac hypertrophy and fibrosis. This obser-
vation also suggests that a lack of responsiveness to TGF-b
could be a new mechanism of myocardial hypertrophy and
heart failure. This hypothesis has been supported by other
studies showing that other members of the TGF-b super-
family play an antihypertrophic role through the Smads in
the heart [27–29]. Transaortic constriction leads to a sig-
nificant increase in cardiac hypertrophy in the Smad3
knockout mice, indicating a beneficial role of Smad3 by
delimiting cardiomyocyte hypertrophic growth [27].
Growth differentiation factor 15 (GDF15) has been dem-
onstrated to have antihypertrophic and cardioprotective
effects via activating Smad2/3 [28]. In addition, cardiac-
specific overexpression of BMP-10 also impairs postnatal
cardiac hypertrophic growth by activating Smad1/5/8
[29]. All these results suggest that endogenous canonical
TGF-b/Smad signaling of cardiomyocyte is required for
maintaining cardiac homeostasis and preventing cardiac
hypertrophy.
Recently, we have revealed that the function of endog-
enous TGF-b/Smad signaling in maintaining cardiac
homeostasis involves the downregulation of miRNAs
inducing cardiac hypertrophy. We show that TGF-b1
inhibits the expression of miR-23a/miR-27a/miR-24-2 and
miR-23b/miR-27b/miR-24-1 clusters at the transcriptional
level [30, 31]. Overexpression of miR-27b promotes
hypertrophic cell growth, whereas knockdown of miR-27b
leads to inhibition of the hypertrophic cell growth caused
by phenylephrine (PE) treatment in vitro. In addition,
transgenic mice with cardiomyocyte-specific overexpres-
sion of miR-27b exhibit cardiac hypertrophy and
dysfunction by directly targeting the peroxisome prolifer-
ator-activated receptor-c (PPAR-c). These results provide
the first, and critical, genetic evidence showing that TGF-
b-regulated miR-27b plays an important role in cardiac
hypertrophy [30]. TGF-b/Smads signaling might elicit its
function in preventing cardiac hypertrophy by down-reg-
ulating other miRNAs. MiR-24 has been demonstrated to
play an important role in participating TGF-b-induced
inhibition of myogenesis. Ectopic expression of miR-24
enhances myogenic differentiation and partially rescued
TGF-b-inhibited myogenesis in the C2C12 myoblast cell
line, while knockdown of miR-24 results in the downreg-
ulation of myogenic differentiation markers [31]. MiR-24
is up-regulated during cardiac hypertrophy from mice in
response to transverse aortic constriction or expression of
activated calcineurin, as well as in idiopathic end-stage
failing human hearts, and overexpression of miR-24 indu-
ces hypertrophic growth of cardiomyocyte in vitro [8].
However, whether the down-regulation of miR-24 plays a
function in TGF-b regulated cardiac homeostasis needs to
be further demonstrated.
MiRNAs regulated by calcineurin signaling
Calcineurin signaling is a major intracellular regulator of
cardiomyocyte growth and function. Activation of the
calcineurin and its downstream targets, transcriptional
effector nuclear factor of activated T-cells (NFATs), results
in cardiac hypertrophy. In a study screening for miRNAs
regulated during cardiac hypertrophy and heart failure, the
transgenic mice expressing activated calcineurin A show
significantly altered expression of miRNAs, suggesting that
miRNA could mediate calcineurin signaling to modulate
the cardiac hypertrophy [8].
MiR-23a has been shown to be upregulated in calci-
neurin A transgenic mice and upon the treatment with the
hypertrophic stimuli including isoproterenol and aldoste-
rone [8, 32]. MiR-23a is up-regulated by NFATc3 at the
transcriptional level, and able to convey the calcineurin/
NFATc3-mediated hypertrophic signal by directly target-
ing the muscle-specific ring finger protein 1, an anti-
hypertrophic protein.
Reciprocal repression between microRNA-133 and cal-
cineurin signaling has been shown to regulate cardiac
hypertrophy. Cardiac hypertrophy in vivo and in vitro
induced by transverse aortic constriction and phenyleph-
rine (PE) treatment involves increased activity and
expression of calcineurin and decreased miR-133 expres-
sion. Treatment of neonatal rat cardiomyocytes or mice
with cyclosporin A, an inhibitor of calcineurin, prevents
the down-regulation of miR-133. Consistently, antisense
oligonucleotides against the catalytic subunit of calcineurin
A and NFAT-specific decoy oligonucleotides could
increase miR-133 expression in cultured primary cardio-
myocytes [33]. Gain-of-function approaches also show that
miR-133 decreases NFAT mRNA levels as well as the
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hypertrophic response to PE-mediated stimulation in pri-
mary cardiomyocytes, and miR-133 loss-of-function leads
to increased NFAT expression and a spontaneous hyper-
trophic response [33].
Recently, miR-199b, which is upregulated in mouse and
human heart failure, has been demonstrated to modulate
calcineurin-NFAT signaling-mediated cardiac hypertrophy
in a positive feedback loop [34]. Calcineurin induces the
expression of miR-199b through a functional NFAT site
about *2.7 kb upstream of the miR-199b gene. MiR-199b
directly targets the dual-specificity tyrosine (Y) phosphor-
ylation-regulated kinase 1a (Dyrk1a), which has been
previously shown to prevent nuclear occupancy of NFATc
transcription factors [35]. Transgenic mice overexpressing
miR-199b, or haploinsufficient for Dyrk1a, exhibit more
exaggerated cardiac hypertrophic phenotype induced by
calcineurin/NFAT signaling or pressure overload. In vivo
inhibition of miR-199b by a specific antagomir normalizes
Dyrk1a expression, reduces nuclear NFAT activity, inhibits
and even reverses the cardiac hypertrophy and fibrosis in
mouse models of heart failure [34].
All these results indicate that miRNAs regulated by
calcineurin can affect cardiac cellular calcineurin signaling
and cardiac homeostasis.
Non-cardiomyocyte miRNAs in cardiac hypertrophy
In addition to cardiomyocytes, the heart contains many
other ‘‘non-cardiomyocyte’’ cell types, such as fibroblasts,
endothelial cells, smooth muscle cells, and immune cells,
which may have completely distinct miRNA and target
gene expression profiles. These non-cardiomyocytes play
important roles in both cardiac hypertrophy and heart failure
by stimulating complex cardiac remodeling, which involves
interstitial fibrosis, angiogenesis, and inflammation. Recent
studies have revealed the essential function of non-cardio-
myocyte miRNAs in maintaining cardiac homeostasis by
regulating cardiac fibrosis and inflammation.
TGF-b signaling-related miRNAs and cardiac fibrosis
Fibroblasts that represent the majority of non-cardiomyo-
cytes in heart are essential for the cardiac adaptive response
to pressure overload [36]. Cardiac fibroblasts produce
extracellular matrix (ECM) proteins, as well as paracrine
factors that can regulate the function of cardiomyocytes.
Reciprocally, the function of fibroblasts could be modu-
lated by paracrine factors secreted by cardiomyocytes.
TGF-b1 is the most important cytokine that contributes to
fibrotic response. It induces fibroblasts to produce ECM
and reduce collagenase production, resulting in an overall
inhibition of ECM degradation and leading to excessive
matrix accumulation. Recent studies reveal that fibroblastic
miRNAs regulated by TGF-b signaling contribute to car-
diac hypertrophy.
MiR-21 is among the most strongly upregulated
miRNAs in response to a variety of forms of cardiac
stresses [37, 38], and induced by TGF-b signaling through
a post-transcriptional step [39, 40]. MiR-21 is specifically
upregulated in cardiac fibroblasts in the failing heart.
Upregulation of miR-21 in cardiac fibroblasts targets the
sprouty homologue 1 (Spry1), thereby indirectly enhancing
the activity of the mitogen-activated protein kinase
(MAPK)/extracellular signal-regulated kinase (ERK) sig-
naling pathway. This positively regulates cardiac fibroblast
survival, leading to fibrosis, hypertrophy, and cardiac
dysfunction [41]. The fibrotic function of miR-21 has been
further confirmed by later studies in models of pulmonary
and renal fibrosis [42, 43]. However, there is obviously
contradictory data about the function of miR-21 in stress-
dependent cardiac remodeling. miR-21-deficient null mice
have been reported to display cardiac hypertrophy and
fibrosis comparable to wild-type littermates in response to
various cardiac stresses, suggesting that miR-21 is not
essential for pathological cardiac remodeling [44]. MiR-21
has also been shown to induce the expression of matrix
metalloproteinase-2 by targeting the phosphatase and ten-
sin homolog (PTEN) in the fibroblasts [45].
The miR-29 family is composed of three members, miR-
29a, b and c, which are preferentially expressed in cardiac
fibroblasts as compared with cardiomyocytes and down-
regulated in the mouse heart in response to TAC, chronic
calcineurin signaling, and in the viable myocardium after
myocardial infarction (MI) [46]. Interestingly, miR-29 is
downregulated after TGF-b stimulation in cultured cardiac
fibroblast, and upregulated in Smad3 knock-out heart,
suggesting that down-regulation of miR-29 could contrib-
ute to TGF-b-induced fibrosis. Studies also show that the
miR-29 family targets mRNAs encoding a multitude of
ECM-related proteins involved in fibrosis, including mul-
tiple collagens, fibrillins, and elastin. Downregulation of
miR-29 with anti-miRs in vitro and in vivo induces the
expression of collagens, whereas overexpression of miR-29
in fibroblasts reduces collagen expression. All these data
indicate that miR-29 acts as a regulator of cardiac fibrosis,
and might serve as a potential therapeutic target for cardiac
fibrosis [46].
MiR-133 and miR-30 have been shown to inhibit car-
diac fibrosis by targeting and connective tissue growth
factor (CTGF). CTGF is considered a key molecule in
inducing ECM synthesis, and positively regulated by TGF-
b [47]. MiR-30 is highly expressed in cardiac fibroblasts,
and may decrease the production of collagens by directly
targeting CTGF. Knockdown of miR-30c in cultured fibro-
blasts increases CTGF expression, whereas overexpression of
miRNAs and cardiac hypertrophy 3565
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miR-30 decreases CTGF. The change of CTGF expression
induced by the miR-30 is accompanied by parallel chan-
ges in collagen expression in fibroblasts. Importantly, a
reduction in miR-30 expression inversely correlates with
CTGF in rodent models of cardiac hypertrophy and
samples from patients with left ventricular hypertrophy
[48]. Although miR-133 is expressed mainly in cardio-
myocyte, its function in regulating fibrosis has been
demonstrated by in vitro and in vivo experiments [49, 50].
Cardiomyocyte-specific overexpression of miR-133a in
mice leads to reduced apoptosis and fibrosis after TAC,
while knockout of the two miR-133a genes results in
dilated cardiomyopathy accompanied by extensive fibro-
sis in surviving mutant mice. Mechanistically, miR-133a
inhibits cardiac fibrosis by directly targeting CTGF,
which regulate the myocardial matrix remodeling through
a paracrine mechanism.
NF-jB regulated miRNA and cardiac inflammation
Accumulated evidence indicates an important role for
inflammation in cardiac hypertrophy and failure. Patients
with HF have elevated levels of a number of inflammatory
cytokines both in the circulation and in the failing
heart itself. Inflammatory cytokines such as tumor necrosis
factor-a (TNF-a), interleukin-1b (IL-1b), NF-jB and
monocyte chemoattractant peptide-1 (MCP-1) may con-
tribute to the development and progression of HF by
promoting myocardial hypertrophy, activating matrix
metalloproteinases, provoking contractile dysfunction, and
inducing apoptosis [51].
NF-jB, the main downstream effector molecule of TLR
(Toll-like receptors) signaling, is a nuclear transcription
factor that increases the expression of proinflammatory
cytokines like TNF-a, IL-1, IL-6, and IFN-c. Persistent
activation of proinflammatory cytokine expression appears
to have detrimental effects on heart. In human heart failure
patients, increased NF-jB activation has been detected
[52]. Whereas chemical NF-jB inhibition largely decreases
myocardial infarct size in rats, indicating a detrimental role
of NF-jB in stressed hearts [53]. These results suggest that
NF-jB is a crucial component in the immune response that
occurs during the development of cardiac hypertrophy and
heart failure.
MiR-146 is abundantly expressed in the heart and is
upregulated upon activation of NF-jB [54]. Considering
that miR-146 is rapidly induced mediated by TLR and
NF-jB in immune cells upon lipopolysaccharides (LPS)
exposure [54], and miR-146 is increased in the cardiomy-
ocyte-specific Dicer-deficient mice that showed signs of
inflammation, this induction probably originates from
inflammatory cells that invade the myocardium [4]. The
increased miR-146 leads to the downregulation of two
downstream mediators of TLR signaling- IRAK and
TRAF6, creating an anti-inflammation feedback loop to
inhibit NF-jB-induced proinflammatory cytokine produc-
tion. In addition, miR-146 is found to be upregulated in
mouse models of MI and TAC [55], implicating that this
miRNAs is involved in the pathogenesis of HF by influ-
encing the inflammatory response. Until now, the role for
miR-146 in heart disease has been unknown; further studies
should be performed to determine its function in the
pathogenesis of cardiac hypertrophy and heart failure.
miRNAs as potential therapeutic targets in cardiac
hypertrophy
The identification of miRNAs as important regulators in
cardiac hypertrophy raises their therapeutic implications in
cardiac diseases. To date, several tools are available to
selectively target miRNA pathways. Chemically engineered
oligonucleotides, termed ‘‘mimic’’ and ‘‘antagomirs’’, and
adenovirus that expresses specific sense or antisense
miRNAs, have been developed and evaluated for their
therapeutic effect on cardiac diseases. Until now, a number
of miRNAs have been proven to be effective therapeutic
targets for cardiac diseases.
Cardiomyocyte miRNAs act as therapeutic targets
Dysregulation of cardiomyocyte miRNAs disturbs cardiac
homeostasis by disrupting the cellular responses of
cardiomyocytes to various signaling pathways. Recent
studies have demonstrated that re-expression of downreg-
ulated anti-hypertrophic miRNAs or knockdown of
upregulated pro-hypertrophic miRNAs is able to modulate
cardiac remodeling, and serve as a promising therapeutic
approach.
In vivo overexpression of anti-hypertrophic miRNAs
attenuates cardiac hypertrophy
MiR-133 is decreased in mouse and human models of
cardiac hypertrophy, and has been shown to inhibit cardiac
hypertrophy by targeting RhoA, Cdc42, and Nelf-A/
WHSC2. To examine whether miR-133 overexpression has
a beneficial effect on cardiac hypertrophy, adenovirus
expressing miR-133 (Ad133) infection is performed in Akt
transgenic mice that develop significant cardiac hypertro-
phy. Overexpression of miR-133 results in a significant
reduction in the size of left ventricular cardiac myocytes
and a significant decrease in the expression of fetal genes,
indicating that miR-133 acts as a therapeutic target for
cardiac hypertrophy [21]. However, another study shows
3566 J. Wang, X. Yang
123
that miR-133a overexpression in postnatal cardiomyocytes
does not alter reactive hypertrophy in pressure-overloaded
or isoproterenol-treated hearts, although it protects against
myocardial fibrosis [50]. The discrepancy indicates that
miR-133a might have a defined range of expression that is
required for preventing cardiac hypertrophy, and suggest
that for any miRNA-directed therapeutic approach may
have to face a narrow therapeutic window.
MiR-98/Let-7 has been demonstrated to mediate the
antihypertrophic effect of thioredoxin (Trx1) [56]. Studies
show that Trx 1 negatively regulates Ang II-induced car-
diac hypertrophy through upregulation of miR-98/let-7. To
evaluate the function of miR-98 in the heart in vivo, Ad-
miR-sc, Ad-miR-98, or Ad-anti–miR-98 has been injected
into mouse hearts, following which mice have been treated
with or without continuous infusion of Ang II. Although
neither Ad-miR-98 nor Ad-anti–miR-98 significantly
affects heart morphology at baseline, Ang II–induced
increases in LVW/BW, LV myocyte cross-sectional area,
cardiac fibrosis, and apoptosis are significantly attenuated
by Ad-miR-98 and significantly enhanced by Ad-anti–miR-
98. These results suggest that miR-98 inhibits Ang II–
induced cardiac hypertrophy and might be a therapeutic
target for cardiac diseases [56].
In vivo inhibition of pro-hypertrophic miRNAs
attenuates cardiac hypertrophy
MiR-23a has been shown to be able to convey the hyper-
trophic signal of ISO stimulation. To test whether
knockdown of miR-23a in vivo can be benefit for cardiac
hypertrophy, antagomir-23a has been delivered into heart
of mice perfusion with ISO. Antagomir-23a inhibits ISO-
induced hypertrophy revealed by heart weight/body weight
ratio, hypertrophic phenotype, cross-sectional areas, the
expression levels of hypertrophic markers, as well as car-
diac size and function. These data suggest the therapeutic
prospect of miR-23a in cardiac hypertrophy [32].
Cardiac-specific knockout of miR-208a prevents car-
diomyocyte hypertrophy or fibrosis upon various cardiac
stresses, suggesting that inhibition of miR-208a might
serve as a therapeutic strategy [16]. The therapeutic
potential of miR-208a has been demonstrated by a recent
study, in which a locked nucleic acid (LNA)-modified
antisense oligonucleotide against miR-208a is delivered
[57]. The inhibition of miR-208a during hypertension-
induced heart failure in Dahl-hypertensive rats significantly
diminishes stress-induced remodeling, prevents pathologi-
cal myosin switching, and improves cardiac function,
overall health, and survival [57].
Overexpression of miR-199b sensitizes the myocardium
to pathological cardiac hypertrophy [34]. To test whether
antagomir-199b can prevent or cure cardiac disease, wild-
type and calcineurin transgenic mice are subjected to TAC
and then treated intraperitoneally with antagomir-199b on
three consecutive days at the age of 14 days after birth.
TAC-induced interstitial fibrosis, cardiac hypertrophy, and
left ventricular dilatation are significantly prevented or
attenuated in mice administrated antagomiR-199b, and
fractional shortening and systolic and diastolic contractile
defects are also normalized, implicating that miR-199b
could serve as a therapeutic target for heart failure [34].
Our recent work demonstrate the therapeutic potential of
miR-27b for cardiac disease. We have injected antagomir-
27b into mice subjected to pressure overload of the left
ventricle by TAC. Expression levels of miR-27b are
increased in mice after the TAC surgery, and are effec-
tively downregulated by antagomir-27b treatments.
Antagomir-27b treatments significantly reverse changes in
its target gene PPAR-c expression caused by pressure
overload in the myocardium, and attenuate TAC-induced
cardiac hypertrophy, interstitial fibrosis, and cardiac dys-
function, suggesting that miR-27b is a novel therapeutic
target for pathological cardiac hypertrophy [30].
Non-cardiomyocyte miRNAs as therapeutic targets
miR-21 has been shown to regulate fibroblast survival and
growth factor secretion to control the extent of interstitial
fibrosis and cardiac hypertrophy, raising the possibility that
inhibition of miR-21 expression in a cardiac disease model
should prevent and cure fibrosis. For example, to test the
preventive and curative potential of silencing of miR-21,
antagomir-21 was injected into mice subjected to pressure
overload of the left ventricle by TAC [41]. Of interest,
inhibition of miR-21 significantly attenuates interstitial
fibrosis, enlarged cardiomyocyte size, cardiac dysfunction
and normalizes the expression of various genes that are
dysregulated after TAC [41], implicating the therapeutic
effect of miR-21 in a cardiac disease setting. However,
another study shows that inhibition of miR-21 by a LNA-
modified antimiR oligonucleotide fails to block the
remodeling response of the heart to various stresses, indi-
cating miR-21 is not essential for pathological cardiac
remodeling [44]. The discrepancy between these two
studies may be due to the different inhibitors and different
delivery methods [58], and this needs to be further clarified
in the future.
Conclusions and perspectives
Recent studies provide clear evidence that miRNAs play
important roles by fine-tuning gene expression in response
to physiological or pathological stress. A number of
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signaling cascades related with cardiac hypertrophy can
modulate hypertrophic response by regulating the expres-
sion of cardiomyocyte and non-cardiomyocyte miRNAs.
More importantly, miRNAs and their regulated signaling
pathways have been demonstrated to be valuable potential
therapeutic targets for cardiac diseases. Nevertheless, fur-
ther investigation is needed to determine how the binding
of multiple miRNAs affects the expression of individual
targeted mRNAs, and how multiple miRNA targets are
interlinked to affect the various pathways and cardiac
remodeling. Recently, a new concept- ‘‘competing endog-
enous RNA (ceRNA)’’ has been proposed to explain how
different types of RNAs, including long non-coding RNAs,
‘‘talk’’ to each other using miRNA response elements
(MREs) as letters of a new language [7]. Hence, further
investigation on the function of miRNAs and their regu-
lated networks may help to decipher the complex
mechanism underlying cardiac hypertrophy and heart fail-
ure, and as a result, it may provide new therapeutic
opportunities for this disease.
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